ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 01/24/2024 at 08:30, 9 months 28 days ago

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program.

Abivax Obefazimod Ulcerative Colitis Clinical Development KOL Investor Event
PRESS RELEASE

published on 01/22/2024 at 08:30, 9 months 30 days ago

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024.

Abivax Obefazimod Ulcerative Colitis Crohn’s Disease Clinical Trials
PRESS RELEASE

published on 10/24/2023 at 22:05, 1 year ago

Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE

published on 10/20/2023 at 16:00, 1 year 1 month ago

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PRESS RELEASE

published on 10/20/2023 at 15:45, 1 year 1 month ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
PRESS RELEASE

published on 10/20/2023 at 15:00, 1 year 1 month ago

Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE

published on 10/20/2023 at 08:45, 1 year 1 month ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PRESS RELEASE

published on 10/19/2023 at 00:00, 1 year 1 month ago

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
PRESS RELEASE

published on 10/16/2023 at 17:40, 1 year 1 month ago

Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
PRESS RELEASE

published on 10/02/2023 at 18:00, 1 year 1 month ago

Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

Accesswire

Published on 11/22/2024 at 00:00, 6 hours 38 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 8 hours 33 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 8 hours 48 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 10 hours 23 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 10 hours 28 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 11 hours 37 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 12 hours 2 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 12 hours 40 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 12 hours 47 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 12 hours 47 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 23 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 11 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 12 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 12 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 22 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE